Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Clinical trial NCT04310397 · TERMINATED

Trial details

NCT number: NCT04310397
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Start date: 2020-01-29
Primary completion: 2023-10-09
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.